Share on StockTwits

Insulet (NASDAQ:PODD) General Counsel R Anthony Diehl unloaded 17,871 shares of the company’s stock on the open market in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $37.09, for a total transaction of $662,835.39. Following the sale, the general counsel now directly owns 47,875 shares of the company’s stock, valued at approximately $1,775,684. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Insulet (NASDAQ:PODD) traded down 0.32% on Friday, hitting $36.92. The stock had a trading volume of 336,824 shares. Insulet has a 1-year low of $28.73 and a 1-year high of $51.31. The stock has a 50-day moving average of $36.07 and a 200-day moving average of $40.72. The company’s market cap is $2.046 billion.

Insulet (NASDAQ:PODD) last released its earnings data on Wednesday, May 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.05. The company had revenue of $69.20 million for the quarter, compared to the consensus estimate of $68.47 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. The company’s revenue for the quarter was up 20.6% on a year-over-year basis. On average, analysts predict that Insulet will post $-0.14 earnings per share for the current fiscal year.

PODD has been the subject of a number of recent research reports. Analysts at Barrington Research upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 15th. They now have a $40.00 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Insulet from $60.00 to $50.00 in a research note on Friday, May 9th. Finally, analysts at Leerink Swann cut their price target on shares of Insulet from $55.00 to $45.00 in a research note on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. Insulet has a consensus rating of “Hold” and a consensus price target of $43.36.

Insulet Corporation is primarily engaged in the development, manufacturing and sale of its OmniPod Insulin Management System (NASDAQ:PODD).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.